BZAD01 是一种选择性 NMDA NR1A/2B 受体拮抗剂。

BZAD01 is a selective NMDA NR1A/2B receptor antagonist.

Parkinsonism was induced by microinjection of the toxin, 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle (MFB) of 40 Sprague-Dawley rats. Parkinsonism and the efficacy of drugs were assessed using a battery of behavioural tests including balance beam, apomorphine-induced rotation, body axis bias or "curling", head position bias and disengage sensorimotor latency test. The main effects were that BZAD01 co-administration prevented chronic levodopa-induced potentiation of apomorphine rotation. However levodopa-treated rats were slower than either controls or BZAD-01-treated rats in the locomotor test[2].

305339-41-7

C16H12F6N2O

362.27

BZAD 01;BZAD-01

DMSO:55 mg/ml (151.82 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years